
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. has demonstrated consistent growth momentum driven primarily by its weight management program, contributing positively to revenue fluctuations in recent quarters. The company's comprehensive telehealth platform positions it favorably for accelerated growth in 2025, bolstered by the strategic addition of accessible weight loss treatments like Wegovy at a significantly reduced cost. Additionally, the integration of various functionalities such as remote testing and digital prescriptions not only enhances patient experience but is also expected to attract a larger subscriber base, thereby potentially increasing overall sales.
Bears say
LifeMD Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include the potential for slower-than-expected growth in telehealth revenue and difficulties in acquiring and retaining new patients, which could hinder the company’s ability to achieve profitability. Additionally, heightened competition within the telehealth market and the risk of potential dilution further exacerbate concerns regarding the company’s financial stability and future performance.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares